JANSSEN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN, and what generic alternatives to JANSSEN drugs are available?
JANSSEN has seventy-nine approved drugs.
There are seventy-eight US patents protecting JANSSEN drugs.
There are two thousand two hundred and sixteen patent family members on JANSSEN drugs in seventy-one countries and four hundred and thirty-one supplementary protection certificates in twenty countries.
Summary for JANSSEN
International Patents: | 2216 |
US Patents: | 78 |
Tradenames: | 75 |
Ingredients: | 51 |
NDAs: | 79 |
Patent Litigation for JANSSEN: | See patent lawsuits for JANSSEN |
PTAB Cases with JANSSEN as patent owner: | See PTAB cases with JANSSEN as patent owner |
Drugs and US Patents for JANSSEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-003 | Sep 20, 2016 | RX | Yes | No | 8,785,403 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | 8,518,987 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Janssen R And D | INTELENCE | etravirine | TABLET;ORAL | 022187-001 | Jan 18, 2008 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Janssen Pharms | VERMOX | mebendazole | TABLET, CHEWABLE;ORAL | 017481-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | 10,478,494 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JANSSEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-001 | Jun 23, 2006 | 8,518,987*PED | ⤷ Sign Up |
Janssen Pharms | CONCERTA | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021121-001 | Aug 1, 2000 | 8,629,179*PED | ⤷ Sign Up |
Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-001 | Jun 23, 2006 | 5,843,946*PED | ⤷ Sign Up |
Janssen Pharms | RISPERDAL | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 021444-004 | Dec 23, 2004 | 6,244,905*PED | ⤷ Sign Up |
Janssen Pharms | CONCERTA | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021121-003 | Dec 8, 2000 | 9,029,416 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
International Patents for JANSSEN Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5466814 | ⤷ Sign Up |
Israel | 286000 | ⤷ Sign Up |
African Regional IP Organization (ARIPO) | 3210 | ⤷ Sign Up |
Hungary | E042037 | ⤷ Sign Up |
New Zealand | 579802 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JANSSEN Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2487162 | 93352 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN SOLVAT DE CELUI-CI ET DARUNAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN SPLVAT DE CELUI-CI, EN PARTICULIER L'ETHANOLATE DE DARUNAVIR; AUTHORISATION NUMBER AND DATE: EU/1/14/967 |
2368550 | CR 2019 00029 | Denmark | ⤷ Sign Up | PRODUCT NAME: APALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1342 20190116 |
1663240 | PA2016045 | Lithuania | ⤷ Sign Up | PRODUCT NAME: RILPIVIRINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
2487166 | CA 2017 00004 | Denmark | ⤷ Sign Up | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG TENOFOVIRALAFENAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
0368388 | SPC/GB07/065 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.